TG Therapeutics, Inc. (TGTX)

TG Therapeutics’ results for the second fiscal quarter of 2026 were mixed versus consensus, with revenue topping expectations while EPS trailed; the company reported the quarter on August 3, 2026. Revenue rose 70.3% to about $240.3 million (up from roughly $141.1 million a year ago) and topped consensus, coming in at $240.3 million versus a $229.8 million estimate (+4.6%). EPS of $0.05 trailed the $0.31 estimate (-84%) and was down from $0.17 a year ago, alongside net income that fell 72.4% year over year to about $7.8 million (from roughly $28.2 million). Profitability remained positive, with gross profit of about $199.1 million translating to a gross margin of roughly 83%, while operating income of around $21.7 million produced an operating margin near 9%. The company generated operating cash flow of about $21.4 million and repurchased roughly $100.0 million of stock during the quarter. For the next period, consensus calls for EPS of $0.36 on revenue of $247.1 million.